Pancreas

(101-21) A Phase 1 Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic, Pharmacokinetic Study of Q702 with a Cohort Expansion at the RP2D in Patients with Advanced Solid Tumors

(108-20) A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications

(115-CA) A phase 1/2 study of RTX-224 for the treatment of patients with advanced solid tumors

(119-17) U01-Biomarkers for Noninvasive and Early Detection of Pancreatic Cancer

(127-21) Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects with Wild-Type TP53 Advanced Solid Tumors

(130-21) A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations

(131-17) A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6 (IT-01)

(131-21) Tumor-Agnostic precision immuno-oncology and somatic targeting rational for you (tapistry) Phase II platform trial

(136-21) A Phase I/II randomized, double-blind, placebo-controlled trial (1-BETTER) examining XB2001 (anti-IL-1⍺ True Human antibody) in combination with ONIVYDE + 5-FU/LV (+folinic acid) in advanced pancreatic cancer

(138-20) Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for First and Second Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer

(141-21) A phase 1/2 open label, multicenter study to assess the safety, pharmacokinetics, and antitumor activity of UCB6114 administered intravenously to participants with advanced solid tumors

(154-21) A Phase 1a/1b Dose Escalation/Expansion Study of TTX080, an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab or Cetuximab, in Patients with Advanced Solid Refractory/Resistant Malignancies

(155-17) 0C 17-1: Phase 1 Multi-center Study of the Safety Pharmacokinetics and Preliminary Efficacy of CBT-101 in Subjects with Advanced Solid Tumors and C-Met Dysregulation

(157-17) FID-007 in Treating Participants With Advanced Solid Tumors

(158-21) A Phase 1/2a, Open-Label, Multi-Center Study Evaluating the Safety, Tolerability, and Anti-Tumor Activity of AFM24 in combination with Ex Vivo Expanded Autologous Natural Killer Cells (SNK01) in Subjects with Advanced/Metastatic EGFR-Expressing Cancers

(160-21) A Phase 1 Study of ZN-c3 as a Single Agent in Subjects with Solid Tumors

(162-20) A Randomized, Prospective, Multi-center Trial to Assess the Efficacy of a Cryotherapy Device Versus Best Supportive Oral Care in Mitigating Symptoms of Oral Mucositis in Patients Receiving Chemotherapy for the Treatment of Cancer

(168-18) Trial to Evaluate Safety and Tolerability of GP-2250 in Combination With Gemcitabine

(173-21) Phase 2, Prospective, Single Arm Medical Food Study to Evaluate a Standardized Nonessential Amino Acid Restriction (NEAAR) Medical Food for the Dietary Management of Metastatic Pancreatic Cancer

(176-21) NP-G2-044 as Monotherapy and Combination Therapy in Patients with Advanced or Metastatic Solid Tumor Malignancies

(178-21) Open-label, multicenter, Phase 1b clinical trial to evaluate the safety and efficacy of autologous anti-claudin18.2 chimeric antigen receptor T-cell therapy in patients with advanced gastric or pancreatic adenocarcinoma

(187-17) Trial of ZW25 in Patients With Advanced HER2-expressing Cancers

(188-18) A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors

(188-20) A Two-Part, Phase II, Multi-center Study of the ERK Inhibitor Ulixertinib (BVD-523) for Patients with Advanced Malignancies Harboring MEK or Atypical BRAF Alterations

(189-19) A Phase 1/2 Dose-Finding Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy

(196-21) A Phase 1 b/2 study of repotrectinib in combination with other anticancer therapies for the treatment of subjects with KRAS-Mutant advanced solid tumor (TRIDENT-2)

(205-19) Study to Assess AFM24 in Advanced Solid Cancers

(209-20) First-In-Human Dose-Escalation Study of SRP1002 in Patients with Advanced-Stage Solid Tumors

(210-21) A Phase 1b Study of Serabelisib in Combination with an Insulin Suppressing Diet (Study ISD) in Subjects with Advanced Solid Tumors with PIK3CA Mutations with or without PTEN loss

(213-20) A First-in-human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients with Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors

(220-21) A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes

(221-19) Study of GNX102 in Patients With Advanced Solid Tumors

(231-20) A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Intravenous Zotatifin (eFT226) in Subjects with SelectedAdvanced Solid Tumor Malignancies

(238-20) Randomized Phase II Trial of Two Different Nutritional Approaches for Patients Receiving Treatment for Their Advanced Pancreatic Cancer

(243-20) Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects with Wild-Type TP53 Advanced Solid Tumors

(256-21) The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population

 

 

Certain clinical trials may not be listed on ClinicalTrials.gov. To learn more about these or other clinical trials, please call 949-764-4577